Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Droxidopa
Drug ID BADD_D00732
Description Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout Europe. Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011. Additionally, phase II clinical trials for intradialytic hypotension are also underway. Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the pharmaceutical company developing it in that country.
Indications and Usage Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Increased levels of norepinephrine in the central nervous system (CNS) may be beneficial to patients in a wide range of indications. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
Marketing Status Prescription
ATC Code C01CA27
DrugBank ID DB06262
KEGG ID D01277
MeSH ID D015103
PubChem ID 92974
TTD Drug ID D0I3RO
NDC Product Code 67386-822; 70771-1611; 38217-0030; 31722-010; 68180-988; 27808-199; 69539-089; 70771-1610; 27241-200; 27241-201; 67877-704; 69539-146; 67386-820; 76278-1120; 69766-032; 59651-377; 69539-088; 67386-821; 69452-257; 31722-015; 53069-1060; 70436-140; 72205-073; 70710-1390; 58159-049; 68180-987; 0832-0720; 0832-0721; 70710-1391; 50228-429; 70710-1389; 63304-104; 70436-141; 70771-1609; 67877-705; 68180-989; 27808-201; 63304-086; 50228-431; 27808-200; 72205-072; 59651-376; 69452-256; 0054-0532; 0832-0722; 0054-0533; 59651-375; 63304-112; 72205-074; 50228-430; 27241-199; 67877-706; 42973-237; 0054-0534; 70436-142; 31722-014; 69452-258
Synonyms Droxidopa | threo-DOPS | threo DOPS | 3,4-threo-DOPS | 3,4 threo DOPS | DL-threo-3,4-Dihydroxyphenylserine | DL threo 3,4 Dihydroxyphenylserine | erythro-3,4-Dihydroxyphenylserine | erythro 3,4 Dihydroxyphenylserine | Droxidopa, (DL-Tyr)-Isomer | 3,4-Dihydroxyphenylserine | 3,4 Dihydroxyphenylserine
Chemical Information
Molecular Formula C9H11NO5
CAS Registry Number 23651-95-8
SMILES C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery occlusion02.02.01.006; 24.04.04.0130.000556%Not Available
Cough22.02.03.001--
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.005--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.000927%
Cystitis11.01.14.001; 20.03.02.0020.001484%
Death08.04.01.0010.031494%
Decreased activity19.11.01.002; 08.01.01.0060.000742%Not Available
Decubitus ulcer23.03.11.0060.000145%Not Available
Dehydration14.05.05.0010.007603%
Delirium19.13.02.001--
Delusion19.10.01.0010.000742%
Dementia19.20.02.001; 17.03.01.0010.000871%Not Available
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.001--Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.0050.001484%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.003894%Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.146320%
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.005749%Not Available
Drooling17.02.05.0050.001113%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug withdrawal convulsions17.12.03.016; 08.06.02.0030.000371%Not Available
Dry eye06.08.02.0010.001113%
Dry mouth07.06.01.0020.003153%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 17 Pages